



W&M ScholarWorks

Arts & Sciences Articles

Arts and Sciences

2010

Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention

J. Fadel

J. A. Burk

William & Mary, jabur2@wm.edu

Follow this and additional works at: <https://scholarworks.wm.edu/aspubs>

Recommended Citation

Fadel, J., & Burk, J. A. (2010). Orexin/hypocretin modulation of the basal forebrain cholinergic system: role in attention. *Brain research*, 1314, 112-123.

This Article is brought to you for free and open access by the Arts and Sciences at W&M ScholarWorks. It has been accepted for inclusion in Arts & Sciences Articles by an authorized administrator of W&M ScholarWorks. For more information, please contact scholarworks@wm.edu.

available at www.sciencedirect.comwww.elsevier.com/locate/brainres
**BRAIN
RESEARCH**

Research Report

Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention

J. Fadel^{a,*}, J.A. Burk^b

^aDepartment of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, 6439 Garners Ferry Road, Columbia, SC 29208, USA

^bCollege of William and Mary, Williamsburg, VA 23187, USA

ARTICLE INFO

Article history:

Accepted 13 August 2009

Available online 21 August 2009

Keywords:

Acetylcholine

Orexin

Hypocretin

Basal forebrain

Attention

Arousal

ABSTRACT

The basal forebrain cholinergic system (BFCS) plays a role in several aspects of attentional function. Activation of this system by different afferent inputs is likely to influence how attentional resources are allocated. While it has been recognized for some time that the hypothalamus is a significant source of projections to the basal forebrain, the phenotype(s) of these inputs and the conditions under which their regulation of the BFCS becomes functionally relevant are still unclear. The cell bodies of neurons expressing orexin/hypocretin neuropeptides are restricted to the lateral hypothalamus and contiguous perifornical area but have widespread projections, including to the basal forebrain. Orexin fibers and both orexin receptor subtypes are distributed in cholinergic parts of the basal forebrain, where application of orexin peptides increases cell activity and cortical acetylcholine release. Furthermore, disruption of orexin signaling in the basal forebrain impairs the cholinergic response to an appetitive stimulus. In this review, we propose that orexin inputs to the BFCS form an anatomical substrate for links between arousal and attention, and that these interactions might be particularly important as a means by which interoceptive cues bias allocation of attentional resources toward related exteroceptive stimuli. Dysfunction in orexin–acetylcholine interactions may play a role in the arousal and attentional deficits that accompany neurodegenerative conditions as diverse as drug addiction and age-related cognitive decline.

© 2009 Elsevier B.V. All rights reserved.

1. Introduction

Since the first reports of their discovery in the late 1990s (de Lecea et al., 1998; Sakurai et al., 1998) the orexin/hypocretin family of neuropeptides has generated a tremendous amount of interest due to their involvement in a variety of important and interesting physiological phenomena, leading to their description as “physiological integrators” (de Lecea et al., 2002). The cell bodies of orexin/hypocretin neurons are confined to

the lateral hypothalamus and contiguous perifornical area, although they project widely to both rostral and caudal brain regions (Peyron et al., 1998). The peptides produced by the *preproorexin* gene act on two G protein-coupled receptors: the orexin/hypocretin 1 receptor (Ox1R/Hcrtr1), which is selective for orexin A (OxA)/hypocretin 1, and the orexin 2 receptor (Ox2R/Hcrtr2), which binds both OxA and orexin B/hypocretin 2 (OxB) with high affinity (Ammoun et al., 2003; Sakurai et al., 1998). More definitive descriptions of the specific roles played

* Corresponding author. Fax: +1 803 733 1523.

E-mail address: jim.fadel@uscmed.sc.edu (J. Fadel).

by these peptides (hereafter referred to as orexins, for simplicity) in certain normal and pathological neural processes will be facilitated by further analysis of their interactions with other brain regions and neurotransmitter systems. The anatomical substrates for these interactions, including for those underlying the putative effects of orexins on attention (the focus of this review), are multitudinous (Peyron et al., 1998). Orexins likely regulate attention and arousal via interactions with a variety of ascending neuromodulatory systems, including dopamine neurons in the ventral midbrain (Fadel and Deutch, 2002; Vittoz and Berridge, 2006) and noradrenergic neurons in the locus coeruleus (Baldo et al., 2003; Espana et al., 2005; Horvath et al., 1999). Our labs, however, have focused primarily on orexin interactions with the basal forebrain cholinergic system (BFCS), the principle extrinsic source of the neurotransmitter acetylcholine (ACh) in the mammalian neocortex and a crucial mediator of several aspects of attentional function. We propose that orexin inputs to the BFCS form an anatomical substrate for links between arousal and attention, and that these interactions might be particularly important as a means by which interoceptive cues bias allocation of attentional resources toward related exteroceptive stimuli.

2. Overview of the basal forebrain cholinergic system role in attention

Attention represents a construct that can be defined and measured based upon manipulation of specific variables, including target number, duration and unpredictability along with the ability to ignore irrelevant stimuli (Parasuraman et al., 1987; Sarter et al., 2001). As has been discussed in other reviews (Sarter et al., 2001), attentional processing requires some generalized state of arousal, or a general physiological state of readiness for action. However, brain mechanisms involved in attention can be dissociated from arousal based upon changes in task performance following manipulation of specifically defined variables known to affect attentional processing.

The BFCS is composed of a group of magnocellular, ACh-utilizing neurons distributed among heterogeneous anatomical structures along the ventral aspect of the mammalian forebrain. This system includes a loosely clustered arrangement of cholinergic neurons located in the nucleus basalis magnocellularis (nBM) and rostrally contiguous ventral pallidum/substantia innominata (VP/SI), termed the Ch4 subgroup by Mesulam et al. (1983a,b). These neurons project diffusely to all layers and areas of the neocortical mantle (Bigl et al., 1982), where the primary physiological effect of ACh is to modulate the response of pyramidal cells to other, particularly glutamatergic, cortical input (McCormick, 1993; Metherate and Ashe, 1993). This innervation of the neocortex by basal forebrain cholinergic neurons is an important mediator of cortical activation in support of cognitive function.

The available evidence suggests that multiple aspects of attention are dependent upon cortical cholinergic inputs arising from the basal forebrain. Pharmacological manipulations of cholinergic receptors in humans are known to affect attentional performance (Bentley et al., 2004). In animals, lesion studies, particularly those employing the immuno-

toxin, 192 IgG-saporin, which selectively destroys cortically projecting basal forebrain cholinergic neurons in rats, have been useful for demonstrating the necessity of the BFCS for attention (McGaughy et al., 2000). For example, accuracy of visual signal detection is decreased in attention-demanding tasks following loss of basal forebrain corticopetal cholinergic neurons (McGaughy et al., 2002, 1996). Performance in divided attention paradigms is also disrupted following intrabasalis infusions of 192 IgG-saporin (Turchi and Sarter, 1997). Moreover, cortical acetylcholine release is elevated during attentional task performance compared with control tasks that limit explicit attentional demands, but that do require similar levels of motoric functioning and that provide similar reinforcement schedules as the attention-demanding task (Arnold et al., 2002; Dalley et al., 2001; Passetti et al., 2000). Thus, the actions of orexins within the basal forebrain on attention can potentially be dissociated with other nonspecific task variables.

3. Anatomical substrates of orexin modulation of the basal forebrain cholinergic system

A series of important primate studies from the 1970s showed that (putatively cholinergic) basal forebrain neurons respond to food-related visual stimuli only when the animal is hungry (Burton et al., 1976; Mora et al., 1976; Rolls et al., 1977, 1979). These observations provided a clear demonstration that the interoceptive state of an animal modulates the response to sensory cues related to physiological status. In other words, homeostatic drive modulates the appetitive salience of a stimulus and the response of neural circuitry underlying attention to that stimulus. While this may seem intuitive, thorough anatomical and phenotypical descriptions of the neural substrates of this relationship have not been forthcoming. What are the neuroanatomical substrates by which information related to physiological status is relayed to neuromodulatory systems involved in attention?

The primary central structure mediating the brain's detection of—and response to—physiological cues from the periphery is the hypothalamus. While the lateral hypothalamus has been classically conceptualized as a “feeding center,” it is also part of the posterior hypothalamus, a major component of the mammalian arousal system (Jones, 2003; Lin et al., 1989; Robinson and Whishaw, 1974; Swett and Hobson, 1968). Thus, this hypothalamic area may be involved in supporting the autonomic and behavioral responses necessary for homeostatic regulation. Because attention, or the ability to detect and select relevant stimuli, requires a generalized state of physiological readiness, i.e., arousal (Robbins, 1997), the afferent regulation of the BFCS by brain regions active in the establishment or maintenance or arousal is of major significance.

Projections from the lateral hypothalamus to the cholinergic basal forebrain have been well-documented and have been hypothesized to relay interoceptive information to this area (Cullinan and Zaborszky, 1991; Zaborszky and Cullinan, 1989). However, phenotypic and functional descriptions of the pathways by which the lateral hypothalamus relays information to rostral brain regions involved in cognitive function have only begun to be elucidated in recent years. As more is learned

about the phenotype and function of ascending hypothalamic projections to areas such as the basal forebrain, a greater appreciation of the role played by these pathways in cognitive and behavioral correlates of age-related hypothalamic dysfunction is likely to emerge.

In recent years a clear anatomical substrate for interactions between orexin neurons and the BFCS has been documented. Hypothalamic projections to cholinergic parts of the basal forebrain were originally described as originating in the far-lateral and medial parts of the lateral hypothalamus (Cullinan and Zaborszky, 1991), a pattern that roughly corresponds to the location of orexin neurons. Indeed, orexin-immunoreactive fibers in the rat distribute widely to various basal forebrain structures (Cutler et al., 1999; Date et al., 1999; Peyron et al., 1998); included among these basal forebrain targets is the

substantia innominata, which receives a predominantly ipsilateral orexin input (España et al., 2005). Because cholinergic neurons of the basal forebrain are not confined to a single, well-circumscribed nucleus, it was important for these orexin inputs to be further characterized specifically with regard to the phenotype of their postsynaptic targets. Orexin-immunoreactive fibers in the substantia innominata and contiguous ventral pallidum make apparent appositional contacts on ChAT-positive, as well as parvalbumin-positive, cells (Fadel et al., 2005) (see also Fig. 1), suggesting the potential for a direct influence of orexins over corticopetal cholinergic and GABAergic projections. While the existence of these postulated monosynaptic connections between orexin fibers and cholinergic neurons awaits ultrastructural confirmation, a combined electron and light microscopic study in the




Fig. 1 – Examples of orexin innervation of cholinergic and GABAergic neurons of the basal forebrain. All photomicrographs were taken from the ventral pallidum/substantia innominata region of the adult (age 3 months) rat basal forebrain (D), following dual-color immunoperoxidase histochemistry using previously described methods (Fadel and Deutch, 2002; Frederick-Duus et al., 2007). (A–C) Double-labeling for ChAT (light brown cell body) and orexin A (black fibers). Arrows indicate points of putative appositional contact between orexin fibers and a cholinergic neuron. Scale bar represents approximately 25 μm . (B) and (C) show different focal planes from the same region, indicating multiple putative z-plane contacts on the proximal dendrite (B) and soma (C) of the same neuron. (E) Double-labeling for the calcium-binding protein parvalbumin (light brown cell bodies), which marks a subset of GABAergic corticopetal basal forebrain neurons, and orexin A (black fibers). Again, orexin fibers are found in high abundance in this region of the basal forebrain, including on and around GABAergic neurons.

brainstem dorsal raphe nucleus has shown that orexin-immunoreactive varicosities observed at the light microscopic level have the ultrastructural appearance of presynaptic axon terminals, with numerous dense core vesicles (Wang et al., 2003). Thus, these varicosities likely represent functional orexin synapses on and around cholinergic somata and perikarya as has already been described for septohippocampal cholinergic neurons (Wu et al., 2004). In addition, retrograde tracer deposits in the basal forebrain label many non-orexin neurons in the area of the lateral hypothalamus (Pasumarthi and Fadel, 2008); although the phenotype of these basal forebrain-projecting, non-orexin neurons remains to be determined, they may represent an additional source of hypothalamic regulation of the BFCS in the context of homeostatic function. However, the available anatomical data clearly demonstrate that orexin neurons contribute substantially to the previously recognized projection from the lateral hypothalamus to the cholinergic basal forebrain (Cullinan and Zaborszky, 1991), implicating the basal forebrain as an integral component of a distributed network that underlies orexin effects on arousal and attention (España et al., 2005).

4. Orexin regulation of basal forebrain cholinergic system activity

Functional descriptions of the importance of orexin–BFCS interactions have derived from electrophysiological, neurochemical and behavioral studies. Although brain orexin levels in general tend to be greatest during wakeful periods, microdialysis across the sleep–wake cycle reveals significant increases in basal forebrain release of OxA during paradoxical, or rapid eye movement (REM) sleep (Kiyashchenko et al., 2002). Electrophysiological data suggest that this may reflect burst discharge of orexin neurons during phasic REM as these cells are largely silent during tonic REM (Mileykovskiy et al., 2005), although given the different time scales of microdialysis and juxtacellular recordings, this relationship between burst discharge and orexin release remains speculative. REM sleep is also associated with activation of corticopetal cholinergic neurons (Jones, 2003; Szymusiak, 1995), suggesting a potential role for orexins in this phenomenon. Clearly, however, Fos expression and *in vivo* electrophysiological data both indicate a high level of orexin neuron activity during transitions to wakefulness (Estabrooke et al., 2001; Lee et al., 2005). Similarly, intrabasalis administration of OxA via reverse microdialysis or direct intracranial infusion increases behavioral indices of wakefulness (España et al., 2001; Thakkar et al., 2001). Intrabasalis administration of orexin A produces robust increases in ACh release within the PFC (Fadel et al., 2005) and amplifies the effects of pedunculopontine tegmentum stimulation on electroencephalograph desynchrony (Dong et al., 2006), suggesting that orexins may increase arousal via complementary and synergistic effects on both basal forebrain and brainstem cholinergic systems (Bernard et al., 2006; Vazquez and Baghdoyan, 2001).

Orexin A activates both types of orexin receptors with roughly equal affinity; hence, effects of this peptide on the basal forebrain cholinergic system do not point to a specific receptor subtype. Furthermore, both Ox1R and Ox2R appear to

be expressed in parts of the basal forebrain that include corticopetal cholinergic neurons (Hervieu et al., 2001; Kilduff and de Lecea, 2001; Marcus et al., 2001) and electrophysiological and neurochemical data are consistent with a role for both Ox1R and Ox2R in activation of the basal forebrain cholinergic system. *In vitro* electrophysiological data indicate that OxB is at least as potent as OxA at exciting basal forebrain cholinergic cells, suggesting primarily an Ox2R-mediated effect (Eggermann et al., 2001). These observations place the basal forebrain cholinergic system within the distributed network underlying the effects of orexins on arousal and wakefulness, as the narcoleptic phenotype associated with loss of orexin neurons or peptides in humans and mice is largely recapitulated in narcoleptic canines with a spontaneously occurring loss-of-function mutation in Ox2R (Lin et al., 1999). However, other studies have suggested that the effects of basal forebrain orexin administration on wakefulness are largely Ox1R-mediated. Lateral ventricular administration of OxA, for example, is more effective than OxB at increasing electroencephalographic, electromyographic and behavioral indices of wakefulness, and these effects are recapitulated with direct intrabasalis administration of OxA (España et al., 2001). Also, in anesthetized rats, intrabasalis administration of OxA is more effective than OxB at increasing somatosensory cortical ACh release and inducing an arousal-like electroencephalograph pattern (Dong et al., 2006). Our studies on the effects of orexins on cortical cholinergic transmission are also consistent with an Ox1R mechanism, as stimulated cortical ACh release under conditions tied to feeding-related arousal is largely blocked by the Ox1R antagonist, SB-334867 (Frederick-Duus et al., 2007). In addition to a primary effect mediated by direct activation of orexin receptors on cholinergic neurons, this may reflect the ability of OxA to increase glutamate release within the basal forebrain (Fadel and Frederick-Duus, 2008). While ultrastructural studies definitively demonstrating the presence of presynaptic orexin receptors on glutamatergic terminals in the basal forebrain have not been reported, these receptors are expressed in sources of presumptive glutamatergic inputs to the basal forebrain, including the prefrontal and insular cortices (Hervieu et al., 2001; Marcus et al., 2001). Ox1R is also expressed in orexin neurons themselves (Backberg et al., 2002), at least some of which colocalize glutamate (Rosin et al., 2003; Torrealba et al., 2003). Finally, several electrophysiological studies have suggested the ability of orexin to increase presynaptic glutamate release in other orexin-receptive brain regions, including the PFC (Lambe et al., 2007), VTA (Borgland et al., 2008) and preoptic area (Kolaj et al., 2008). Collectively, these studies support the hypothesis that, in addition to direct effects, orexins may excite basal forebrain cholinergic neurons via presynaptic glutamatergic mechanisms.

The current data do not allow for definitive conclusions regarding which of the orexin receptor subtypes is most heavily involved in activation of the BFCS. Indeed, the two receptors may play different, but complementary roles in response to varying types of homeostatic challenges. Ultrastructural studies documenting the precise presynaptic and postsynaptic localization of Ox1R and Ox2R within the basal forebrain as well as commercial availability of additional selective agonists and antagonists of these receptors will

provide much-needed anatomical and pharmacological data concerning the mechanisms and functional contexts underlying orexin effects on basal forebrain cholinergic neurons.

5. Physiological determinants of orexin–ACh interactions

Given the integrative role of orexin neurons, characterizing the specific contribution of these peptides to activation of the BFCS in response to cues related to physiological homeostasis is important. Orexin neurons are sensitive to a number of peripherally derived circulating factors whose fluctuations provide information about homeostatic status, including leptin, ghrelin and glucose (Burdakov and Gonzalez, 2009; Burdakov et al., 2006; Hakansson et al., 1999; Sakurai, 2005). Food deprivation increases expression of orexin peptides and/or receptors (Kurose et al., 2002; Lu et al., 2000) and orexins are important for food anticipatory-related arousal in fasted animals (Akiyama et al., 2004; Mieda et al., 2004), strongly implicating the orexin system in cholinergic activation by stimuli of homeostatic relevance. Consistent with this hypothesis, we have shown that the normal, robust, cholinergic response to palatable food reward in food-restricted rats is dramatically blunted by pretreatment with the Ox1R antagonist SB-334867 or by immunotoxic lesions that destroy orexin neurons (Frederick-Duus et al., 2007). Importantly, the SB-334867 effects were recapitulated by intrabasalis administration of the drug, indicating that orexin regulation of the BFCS under these conditions does not merely reflect transsynaptic effects mediated by brainstem arousal systems. Furthermore, behaviorally, Ox1R antagonism is associated with increased latency to approach and consume a food reward. It has been suggested that orexin effects on feeding are secondary to their role in regulating arousal threshold (Sutcliffe and de Lecea, 2002). A cognitive correlate to this hypothesis is that orexins, via interactions with areas such as the BFCS, are important for attention to both the interoceptive components of a physiological challenge (“How do I feel?”) and the detection and processing of exteroceptive stimuli related to interoceptive state (“Which sensory cues in my environment are salient?”). Accordingly, ascending inputs to the orexin neurons suggest substrates for regulation beyond those limited to metabolic cues, but also derive from brainstem regions that may convey information regarding arousal, pain and visceral status (Sakurai et al., 2005; Yoshida et al., 2006). Psychological stress states, such as those that accompany fear and anxiety, may represent an additional interoceptive cue whose autonomic, behavioral and cognitive correlates may depend in part on the orexin system (Lambe et al., 2007; Mathew et al., 2008). Neurotoxic lesions of the perifornical hypothalamus, for example, abolish the cardiovascular and behavioral components of conditioned fear (Furlong and Carrive, 2007). Interestingly, our recent preliminary data indicate that orexin neurons are also activated by the anxiogenic benzodiazepine partial inverse agonist FG-7142 (Fig. 2), whose autonomic and cognitive effects are mediated in part via the basal forebrain cholinergic system (Berntson et al., 1996; Moore et al., 1995). Orexin neurons, then, are strategically located to regulate the activity of the BFCS in response to a wide variety of interoceptive cues. Disruptions in




Fig. 2 – Activation of orexin neurons by FG-7142. Adult male rats were treated acutely with the anxiogenic benzodiazepine partial inverse agonist FG-7142 (8.0 mg/kg; i.p.) or vehicle and sacrificed 2 h later. Brains were processed for double-label immunohistochemistry for Fos (black nuclei) and orexin (light brown cytoplasmic staining) using previously described methods (Fadel et al., 2002; Pasumarthi and Fadel, 2008). Few double-labeled cells are seen following vehicle treatment (A). FG-7142 treatment (B) produced a robust activation of perifornical orexin neurons as seen in this cluster of double-labeled cells (arrows). Scale bar represents approximately 100 μm .

these interactions may contribute to attentional dysfunction in a variety of neuropsychiatric conditions, as discussed below.

6. Orexin regulation of attention

Alterations of attentional processing related to disruptions of cholinergic functioning have been associated with numerous neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia and drug addiction (Brousseau et al., 2007; Field and Cox, 2008; Sarter et al., 2005b). Attentional dysfunction may lead to disruptions of working memory or bias processing for specific environmental cues (Sarter et al., 2005a; Sarter and Turchi, 2002). Thus, disrupted attention may contribute to other symptoms associated with some disorders.

We have reported that systemic administration of the OX1R antagonist, SB-334867, decreases signal detection in a two-lever attention task requiring discrimination of visual signals from trials with no signal presentation (Boschen et al., 2009) (see also Fig. 3). A similar pattern of impairment, a decrease in signal detection, has been reported following loss of basal forebrain corticopetal cholinergic neurons (McGaughy et al., 1999, 1996). When SB-334867 was administered directly into the basal forebrain before performance in this task, we




Fig. 3 – Effects of orexin-1 receptor blockade on attentional performance. The figure depicts the significant effects of systemic (A) or intrabasalis (B) SB-334867 in an attention-demanding task that required discrimination of brief visual signals from trials with no signal presentation. Systemic SB-334867 (5.0 mg/kg; i.p.) significantly decreased signal detection following the 500-ms signal (relative hits; denoted by the asterisk), effects similar to those observed following loss of basal forebrain corticopetal cholinergic inputs (McGaughy et al., 1999; McGaughy and Sarter, 1998). Intrabasalis SB-334867 (60 µg) decreased accuracy on a sustained attention (SAT) measure, which takes into account accuracy on trials with and without signal presentation (denoted by the asterisk). This decrease in overall accuracy may reflect that SB-334867 also affected non-cholinergic basal forebrain corticopetal cholinergic neurons (Burk and Sarter, 2001; Sarter and Bruno, 2002). The figure is modified from Boschen et al. (2009). Error bars represent SEMs.

observed decreases in an overall measure of accuracy that takes into account performance on trials with signals and without signal presentation. Thus, intrabasalis SB-334867 also produced a marginal decrease in accuracy on no signal trials. Ibotenic acid-induced basal forebrain lesions, which produce relatively greater damage to non-cholinergic basal forebrain neurons compared to cholinergic neurons, also decrease accuracy in this task on trials when no signal is presented (Burk and Sarter, 2001). Thus, we concluded that orexinergic inputs onto cholinergic and non-cholinergic basal forebrain neurons represent an important system for regulating attentional processing. Interactions between cortical ACh and GABA have been discussed, but remain poorly understood (Sarter and Bruno, 2002). Prefrontal cortical inputs to the basal forebrain make synapses onto neurons that putatively release GABA (Gritti et al., 1997; Zaborszky et al., 1997). Collectively, the available evidence suggests that orexinergic inputs can modulate basal forebrain cholinergic and non-cholinergic neurons, which may, in turn, affect prefrontal cortical processing. Dysregulation of orexin inputs to the basal forebrain may contribute to attentional deficits in some disorders, as discussed in more detail below. Orexins have also been implicated in learning and memory, with orexin A enhancing performance in active and passive avoidance procedures (Jaeger et al., 2002; Telegdy and Adamik, 2002). Cortical cholinergic inputs have been hypothesized to contribute to learning and memory, particularly in tasks that place high demands on attentional processing (Sarter et al., 2003). Thus, alterations in attention associated with pharmacological manipulation of orexin receptors may contribute to some of the effects of orexins on learning and memory (Boschen et al., 2009; Sarter et al., 2003). However, caution is warranted in these conclusions as the effects of orexin A or B administration on performance in attention-demanding tasks have not been reported.

7. Narcolepsy

Post-mortem studies have clearly demonstrated that human narcolepsy is associated with a loss of orexin peptides (Nishino et al., 2000; Peyron et al., 2000; Thannickal et al., 2000). Similarly, the spontaneously occurring form of canine narcolepsy is associated with a loss-of-function mutation in Ox2R (Lin et al., 1999) and orexin knockout mice display a narcoleptic phenotype (Chemelli et al., 1999). Interestingly, narcoleptic patients demonstrate attentional deficits even during periods of normal wakefulness (Naumann et al., 2006; Rieger et al., 2003), consistent with a role for the orexin system in some aspects of cognition. Canine narcolepsy is also associated with neurodegeneration in parts of the basal forebrain (Siegel et al., 1999), suggesting that a primary deficit in orexin signaling might contribute to postsynaptic degeneration and impaired ACh-dependent cognitive function.

8. Drug addiction and relapse

A clear role is emerging for the orexin system in responses to drugs of abuse. Orexin neurons are activated by a variety of psychostimulant drugs, including nicotine (Pasumarthi et al.,

2006), amphetamine (Fadel et al., 2002), methamphetamine (Estabrooke et al., 2001) and the wake-promoting drug modafinil (Scammell et al., 2000). Morphine-conditioned place preference is associated with activation of lateral hypothalamic orexin neurons in a manner that suggests the involvement of this subgroup of orexin neurons in reward (Harris et al., 2005, 2007). Orexin transmission in the VTA appears to play an essential role in the physiological and behavioral correlates of repeated cocaine administration (Borgland et al., 2006). Furthermore, an Ox1R antagonist has recently been shown to attenuate self-administration of nicotine in rats, perhaps via circuitry involving the insular cortex (Hollander et al., 2008). What role might orexin actions in the basal forebrain cholinergic system play in these phenomena?

We have recently shown that acute nicotine administration increases expression of the immediate-early gene product, Fos, in orexin neurons that project to the basal forebrain and paraventricular nucleus of the dorsal thalamus (Pasumarthi and Fadel, 2008). This suggests that ascending orexin projections may be important for coordinating the arousal and attentional correlates of nicotine administration. Repeated nicotine or amphetamine administration sensitizes cortical ACh release and the behavioral correlates of this neurochemical response suggest that this may underlie alterations of attentional processing (Arnold et al., 2003; Deller and Sarter, 1998; Nelson et al., 2000). Similarly, the ability of insular cortex SB-334867 to block nicotine self-administration (Hollander et al., 2008) is consistent with clinical data pointing to an important role of the insula in nicotine addiction (Naqvi et al., 2007) as well as the hypothesized role of this cortical region in interoception (Craig, 2002). In addition to serving as a site of convergence of cholinergic and orexin inputs, the insular cortex is a major source of cortical projections back to the basal forebrain in primates and rodents (Carnes et al., 1990; Mesulam and Mufson, 1984; Zaborszky et al., 1997). Collectively, this suggests that orexins may coordinate attention to interoceptive and exteroceptive cues related to psychostimulant drugs of abuse (Fig. 4). Interestingly, orexin neurons appear to receive a reciprocal innervation from cholinergic neurons of the basal forebrain (Sakurai et al., 2005), and ACh depolarizes orexin neurons (Yamanaka et al., 2003). Recent studies in our lab demonstrate that nicotine increases ACh release in the LH/PFA (Pasumarthi and Fadel, 2006), suggesting that, in addition to the effect of orexins on the BFCS, cholinergic inputs to the hypothalamus may recruit orexin neurons in a “top-down” fashion, allowing for enhancement of general arousal in response to the detection of salient external cues.

It is becoming increasingly clear that the orexin system plays a crucial role in the neuroplasticity that underlies several aspects of repeated psychostimulant administration in animal models (Bonci and Borgland, 2009; Borgland et al., 2006; Boutrel et al., 2005; Wang et al., 2009). The absence of orexin neurons in narcoleptic patients with cataplexy has been suggested to underlie anecdotal reports of the reduced susceptibility of these patients to stimulant abuse and addiction (Zeitzer et al., 2006). Psychostimulant abuse can produce “hyper-attentional” impairments—defined as the compulsive processing of drug-related cues to the exclusion of other environmental cues—that may predispose to relapse by pathological processing of drug-related stimuli (Jovanovski




Fig. 4 – Hypothetical summary model of orexin regulation of cholinergic projections to prefrontal (PFC) and insular (IC) cortices, based on known anatomical relationships. ACh neurons from the basal forebrain cholinergic system (BFCS) have widespread cortical projections, including to PFC and IC. The involvement of the PFC in executive function and the putative role of the IC as “interoceptive cortex” suggest that the BFCS may influence exteroceptive and interoceptive attention via projections to these areas, respectively. Orexin neurons of the lateral hypothalamus and perifornical area (green stars), as integral components of the hypothalamic circuitry responsive to physiological signals, may allow for coordinated activation of rostral attentional circuitry, ultimately allowing for biased allocation of attentional resources toward stimuli related to physiological status. Alterations in these interactions may contribute to a number of neuropsychiatric conditions in which individual components of these pathways have been implicated, including drug addiction or relapse and the anorexia of aging.

et al., 2005). These impairments have been hypothesized to be mediated through the BFCS, suggesting a possible role for orexin–ACh interactions (Nelson et al., 2000; Sarter et al., 2005a; Williams and Adinoff, 2008). Thus, it seems reasonable to hypothesize that orexin regulation of basal forebrain cholinergic inputs to cortical areas such as the PFC and insula may enhance attentional processing of external, drug-related cues and internal cues related to the aversive state that accompanies, for example, withdrawal.

9. Aging

There is little evidence for frank degeneration, in the form of substantial cell loss, of the orexin system solely as a function of age in humans or animal models. However, a compelling body of data is beginning to accumulate suggesting that aging may

be associated with a decline in expression of orexins or their receptors as well as decreased innervation of certain target structures. For example, aging is associated with decreased Ox2R expression in several brain regions in mice (Terao et al., 2002). Aging has also been shown to decrease levels of both OxA and OxB, as well as their common precursor, prepro-orexin, in the rat brain (Porkka-Heiskanen et al., 2004). Old rats have decreased cerebrospinal fluid orexin levels across the sleep–wake cycle (Desarnaud et al., 2004). Altered innervation of brainstem structures, including a decrease in orexin-immunoreactive fibers in the locus coeruleus, has been reported (Zhang et al., 2002). Similarly, our own preliminary data indicate that aged rats have reduced numbers of putative appositional contacts on and around ChAT-positive cell bodies in the basal forebrain (Frederick-Duus et al., 2008). What might be the implications of age-related changes in the orexin system for basal forebrain cholinergic function?

An early and consistent feature of age-related changes in cognitive function, ranging from mild cognitive impairment to Alzheimer's disease, is a decline in attentional capacity (Oken et al., 1994; Sarter and Turchi, 2002; Scinto et al., 1994). These deficits likely reflect alterations in several interacting neurotransmitter systems, including a prominent role for the corticopetal cholinergic system (Hasselmo and McGaughy, 2004; Muir et al., 1992; Robbins et al., 1997; Sarter and Bruno, 1997; Whitehouse, 2004). However, while severe and late stage dementia is clearly marked by a loss of cholinergic neurons and markers of cholinergic activity (Mufson et al., 2002; Rossor et al., 1982; Whitehouse et al., 1982), frank loss of basal forebrain cholinergic neurons does not consistently appear to be the earliest or most pronounced neuropathological alteration in these disorders or in animal models of aging (Cummings and Benson, 1987; Kurosawa et al., 1989; Mesulam, 2004; Mesulam et al., 1987). This suggests that age-related decline in certain cognitive functions putatively mediated by the cholinergic system may stem, in part, from a failure of normal afferent regulation of the BFCS. Alterations in hypothalamic, including orexin, modulation of the cholinergic system is likely to contribute to these changes. Interestingly, recent evidence shows that changes in homeostatic measures such as food intake and body weight may precede, and indeed predict, subsequent cognitive decline; in some cases, these studies reveal an association between Alzheimer's disease and unexplained weight loss as many as 10 years prior to the onset of frank dementia (Buchman et al., 2005; Grundman, 2005; Johnson et al., 2006). The factors underlying age-related changes in homeostatic regulation and cognition are assuredly heterogeneous and multifactorial (Chapman et al., 2002; Horwitz et al., 2002; Wurtman, 1988). However, a failure of brain regions involved in homeostatic regulation (e.g., the orexin system) to activate other brain regions (e.g., the BFCS) that mediate the appropriate behavioral and cognitive responses to homeostatic challenges such as food or water deprivation may mechanistically link these disparate phenomena.

10. Conclusion

Hypothalamic regulation of the BFCS represents a pathway by which interoceptive information gains access to attentional

mechanisms. Orexin neurons are quantitatively and functionally significant contributors to this pathway. Dysfunction in orexin–acetylcholine interactions may play a role in the arousal and attentional deficits that accompany neurodegenerative conditions as diverse as drug addiction and age-related cognitive decline.

Acknowledgments

This work was supported in part by grants from the American Federation for Aging Research (J.F.) and the National Institutes of Health R01AG030646 (J.F. and J.A.B.).

REFERENCES

- Akiyama, M., Yuasa, T., Hayasaka, N., Horikawa, K., Sakurai, T., Shibata, S., 2004. Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice. *Eur. J. Neurosci.* 20, 3054–3062.
- Ammoun, S., Holmqvist, T., Shariatmadari, R., Oonk, H.B., Detheux, M., Parmentier, M., Akerman, K.E., Kukkonen, J.P., 2003. Distinct recognition of OX1 and OX2 receptors by orexin peptides. *J. Pharmacol. Exp. Ther.* 305, 507–514.
- Arnold, H., Burk, J., Hodgson, E., Sarter, M., Bruno, J., 2002. Differential cortical acetylcholine release in rats performing a sustained attention task versus behavioral control tasks that do not explicitly tax attention. *Neuroscience* 114, 451.
- Arnold, H.M., Nelson, C.L., Sarter, M., Bruno, J.P., 2003. Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. *Psychopharmacology (Berl)* 165, 346–358.
- Backberg, M., Hervieu, G., Wilson, S., Meister, B., 2002. Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake. *Eur. J. Neurosci.* 15, 315–328.
- Baldo, B.A., Daniel, R.A., Berridge, C.W., Kelley, A.E., 2003. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. *J. Comp. Neurol.* 464, 220–237.
- Bentley, P., Husain, M., Dolan, R.J., 2004. Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory. *Neuron* 41, 969–982.
- Bernard, R., Lydic, R., Baghdoyan, H.A., 2006. Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate G protein subtypes in rat pontine reticular formation. *J. Pharmacol. Exp. Ther.* 317, 163–171.
- Berntson, G.G., Hart, S., Ruland, S., Sarter, M., 1996. A central cholinergic link in the cardiovascular effects of the benzodiazepine receptor partial inverse agonist FG 7142. *Behav. Brain Res.* 74, 91–103.
- Bigl, V., Woolf, N.J., Butcher, L.L., 1982. Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: a combined fluorescent tracer and acetylcholinesterase analysis. *Brain Res. Bull.* 8, 727–749.
- Bonci, A., Borgland, S., 2009. Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. *Neuropharmacology* 56 (Suppl. 1), 107–111.
- Borgland, S.L., Taha, S.A., Sarti, F., Fields, H.L., Bonci, A., 2006. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. *Neuron* 49, 589–601.
- Borgland, S.L., Storm, E., Bonci, A., 2008. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. *Eur. J. Neurosci.* 28, 1545–1556.

- Boschen, K.E., Fadel, J.R., Burk, J.A., 2009. Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. *Psychopharmacology (Berl)* 206, 205–13.
- Boutrel, B., Kenny, P.J., Specio, S.E., Martin-Fardon, R., Markou, A., Koob, G.F., de Lecea, L., 2005. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc. Natl. Acad. Sci. U. S. A.* 102, 19168–19173.
- Brousseau, G., Rourke, B.P., Burke, B., 2007. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. *Exp. Clin. Psychopharmacol.* 15, 546–554.
- Buchman, A.S., Wilson, R.S., Bienias, J.L., Shah, R.C., Evans, D.A., Bennett, D.A., 2005. Change in body mass index and risk of incident Alzheimer disease. *Neurology* 65, 892–897.
- Burdakov, D., Gonzalez, J.A., 2009. Physiological functions of glucose-inhibited neurones. *Acta Physiol. (Oxf)* 195, 71–78.
- Burdakov, D., Jensen, L.T., Alexopoulos, H., Williams, R.H., Fearon, I.M., O'Kelly, I., Gerasimenko, O., Fugger, L., Verkhratsky, A., 2006. Tandem-pore K⁺ channels mediate inhibition of orexin neurons by glucose. *Neuron* 50, 711–722.
- Burk, J.A., Sarter, M., 2001. Dissociation between the attentional functions mediated via basal forebrain cholinergic and GABAergic neurons. *Neuroscience* 105, 899–909.
- Burton, M.J., Rolls, E.T., Mora, F., 1976. Effects of hunger on the responses of neurons in the lateral hypothalamus to the sight and taste of food. *Exp. Neurol.* 51, 668–677.
- Carnes, K.M., Fuller, T.A., Price, J.L., 1990. Sources of presumptive glutamatergic/aspartatergic afferents to the magnocellular basal forebrain in the rat. *J. Comp. Neurol.* 302, 824–852.
- Chapman, I.M., MacIntosh, C.G., Morley, J.E., Horowitz, M., 2002. The anorexia of ageing. *Biogerontology* 3, 67–71.
- Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammell, T., Lee, C., Richardson, J.A., Williams, S.C., Xiong, Y., Kisanuki, Y., Fitch, T.E., Nakazato, M., Hammer, R.E., Saper, C.B., Yanagisawa, M., 1999. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* 98, 437–451.
- Craig, A.D., 2002. How do you feel? Interoception: the sense of the physiological condition of the body. *Nat. Rev. Neurosci.* 3, 655–666.
- Cullinan, W.E., Zaborszky, L., 1991. Organization of ascending hypothalamic projections to the rostral forebrain with special reference to the innervation of cholinergic projection neurons. *J. Comp. Neurol.* 306, 631–667.
- Cummings, J.L., Benson, D.F., 1987. The role of the nucleus basalis of Meynert in dementia: review and reconsideration. *Alzheimer Dis. Assoc. Disord.* 1, 128–155.
- Cutler, D.J., Morris, R., Sheridhar, V., Wattam, T.A., Holmes, S., Patel, S., Arch, J.R., Wilson, S., Buckingham, R.E., Evans, M.L., Leslie, R.A., Williams, G., 1999. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. *Peptides* 20, 1455–1470.
- Dalley, J.W., McLaughly, J., O'Connell, M.T., Cardinal, R.N., Levita, L., Robbins, T.W., 2001. Distinct changes in cortical acetylcholine and noradrenaline efflux during contingent and noncontingent performance of a visual attentional task. *J. Neurosci.* 21, 4908–4914.
- Date, Y., Ueta, Y., Yamashita, H., Yamaguchi, H., Matsukura, S., Kangawa, K., Sakurai, T., Yanagisawa, M., Nakazato, M., 1999. Orexins, orexinergic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. *Proc. Natl. Acad. Sci. U. S. A.* 96, 748–753.
- de Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., Fukuhara, C., Battenberg, E.L., Gautvik, V.T., Bartlett II, F.S., Frankel, W.N., van den Pol, A.N., Bloom, F.E., Gautvik, K.M., Sutcliffe, J.G., 1998. The hypothalamus: hypothalamic-specific peptides with neuroexcitatory activity. *Proc. Natl. Acad. Sci. U. S. A.* 95, 322–327.
- de Lecea, L., Sutcliffe, J.G., Fabre, V., 2002. Hypocretins/orexins as integrators of physiological information: lessons from mutant animals. *Neuropeptides* 36, 85–95.
- Deller, T., Sarter, M., 1998. Effects of repeated administration of amphetamine on behavioral vigilance: evidence for "sensitized" attentional impairments. *Psychopharmacology (Berl)* 137, 410–414.
- Desarnaud, F., Murillo-Rodriguez, E., Lin, L., Xu, M., Gerashchenko, D., Shiromani, S.N., Nishino, S., Mignot, E., Shiromani, P.J., 2004. The diurnal rhythm of hypocretin in young and old F344 rats. *Sleep* 27, 851–856.
- Dong, H.L., Fukuda, S., Murata, E., Zhu, Z., Higuchi, T., 2006. Orexins increase cortical acetylcholine release and electroencephalographic activation through orexin-1 receptor in the rat basal forebrain during isoflurane anesthesia. *Anesthesiology* 104, 1023–1032.
- Eggermann, E., Serafin, M., Bayer, L., Machard, D., Saint-Mleux, B., Jones, B.E., Muhlethaler, M., 2001. Orexins/hypocretins excite basal forebrain cholinergic neurones. *Neuroscience* 108, 177–181.
- Espana, R.A., Baldo, B.A., Kelley, A.E., Berridge, C.W., 2001. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. *Neuroscience* 106, 699–715.
- Espana, R.A., Reis, K.M., Valentino, R.J., Berridge, C.W., 2005. Organization of hypocretin/orexin efferents to locus coeruleus and basal forebrain arousal-related structures. *J. Comp. Neurol.* 481, 160–178.
- Estabrooke, I.V., McCarthy, M.T., Ko, E., Chou, T.C., Chemelli, R.M., Yanagisawa, M., Saper, C.B., Scammell, T.E., 2001. Fos expression in orexin neurons varies with behavioral state. *J. Neurosci.* 21, 1656–1662.
- Fadel, J., Deutch, A.Y., 2002. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. *Neuroscience* 111, 379–387.
- Fadel, J., Frederick-Duus, D., 2008. Orexin/hypocretin modulation of the basal forebrain cholinergic system: insights from in vivo microdialysis studies. *Pharmacol. Biochem. Behav.* 90, 156–162.
- Fadel, J., Bubser, M., Deutch, A.Y., 2002. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. *J. Neurosci.* 22, 6742–6746.
- Fadel, J., Pasumarthi, R., Reznikov, L.R., 2005. Stimulation of cortical acetylcholine release by orexin A. *Neuroscience* 130, 541–547.
- Field, M., Cox, W.M., 2008. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. *Drug Alcohol Depend.* 97, 1–20.
- Frederick-Duus, D., Guyton, M.F., Fadel, J., 2007. Food-elicited increases in cortical acetylcholine release require orexin transmission. *Neuroscience* 149, 499–507.
- Frederick-Duus, D., Wilson, S.P., Fadel, J., 2008. Modulation of the orexin/hypocretin system in young and aged rats using lentivirus-mediated gene transfer: effects on cortical acetylcholine release. *Soc. Neurosci. Abst.* 38, 592.7.
- Furlong, T., Carrive, P., 2007. Neurotoxic lesions centered on the perifornical hypothalamus abolish the cardiovascular and behavioral responses of conditioned fear to context but not of restraint. *Brain Res.* 1128, 107–119.
- Gritti, I., Mainville, L., Mancia, M., Jones, B.E., 1997. GABAergic and other noncholinergic basal forebrain neurons, together with cholinergic neurons, project to the mesocortex and isocortex in the rat. *J. Comp. Neurol.* 383, 163–177.
- Grundman, M., 2005. Weight loss in the elderly may be a sign of impending dementia. *Arch. Neurol.* 62, 20–22.
- Hakansson, M., de Lecea, L., Sutcliffe, J.G., Yanagisawa, M., Meister, B., 1999. Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. *J. Neuroendocrinol.* 11, 653–663.
- Harris, G.C., Wimmer, M., Aston-Jones, G., 2005. A role for lateral

- hypothalamic orexin neurons in reward seeking. *Nature* 437, 556–559.
- Harris, G.C., Wimmer, M., Randall-Thompson, J.F., Aston-Jones, G., 2007. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. *Behav. Brain Res.* 183, 43–51.
- Hasselmo, M.E., McGaughy, J., 2004. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. *Prog. Brain Res.* 145, 207–231.
- Hervieu, G.J., Cluderay, J.E., Harrison, D.C., Roberts, J.C., Leslie, R.A., 2001. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. *Neuroscience* 103, 777–797.
- Hollander, J.A., Lu, Q., Cameron, M.D., Kamenecka, T.M., Kenny, P.J., 2008. Insular hypocretin transmission regulates nicotine reward. *Proc. Natl. Acad. Sci. U. S. A.* 105, 19480–19485.
- Horvath, T.L., Peyron, C., Diano, S., Ivanov, A., Aston-Jones, G., Kilduff, T.S., van Den Pol, A.N., 1999. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J. Comp. Neurol.* 415, 145–159.
- Horwitz, B.A., Blanton, C.A., McDonald, R.B., 2002. Physiologic determinants of the anorexia of aging: insights from animal studies. *Annu. Rev. Nutr.* 22, 417–438.
- Jaeger, L.B., Farr, S.A., Banks, W.A., Morley, J.E., 2002. Effects of orexin-A on memory processing. *Peptides* 23, 1683–1688.
- Johnson, D.K., Wilkins, C.H., Morris, J.C., 2006. Accelerated weight loss may precede diagnosis in Alzheimer disease. *Arch. Neurol.* 63, 1312–1317.
- Jones, B.E., 2003. Arousal systems. *Front Biosci.* 8, s438–s451.
- Jovanovski, D., Erb, S., Zakzanis, K.K., 2005. Neurocognitive deficits in cocaine users: a quantitative review of the evidence. *J. Clin. Exp. Neuropsychol.* 27, 189–204.
- Kilduff, T.S., de Lecea, L., 2001. Mapping of the mRNAs for the hypocretin/orexin and melanin-concentrating hormone receptors: networks of overlapping peptide systems. *J. Comp. Neurol.* 435, 1–5.
- Kiyashchenko, L.I., Mileykovskiy, B.Y., Maidment, N., Lam, H.A., Wu, M.F., John, J., Peever, J., Siegel, J.M., 2002. Release of hypocretin (orexin) during waking and sleep states. *J. Neurosci.* 22, 5282–5286.
- Kolaj, M., Coderre, E., Renaud, L.P., 2008. Orexin peptides enhance median preoptic nucleus neuronal excitability via postsynaptic membrane depolarization and enhancement of glutamatergic afferents. *Neuroscience* 155, 1212–1220.
- Kurosawa, M., Sato, A., Sato, Y., 1989. Well-maintained responses of acetylcholine release and blood flow in the cerebral cortex to focal electrical stimulation of the nucleus basalis of Meynert in aged rats. *Neurosci. Lett.* 100, 198–202.
- Kurose, T., Ueta, Y., Yamamoto, Y., Serino, R., Ozaki, Y., Saito, J., Nagata, S., Yamashita, H., 2002. Effects of restricted feeding on the activity of hypothalamic orexin (OX)-A containing neurons and OX2 receptor mRNA level in the paraventricular nucleus of rats. *Regul. Pept.* 104, 145–151.
- Lambe, E.K., Liu, R.J., Aghajanian, G.K., 2007. Schizophrenia, hypocretin (orexin), and the thalamocortical activating system. *Schizophr. Bull.* 33, 1284–1290.
- Lee, M.G., Hassani, O.K., Jones, B.E., 2005. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J. Neurosci.* 25, 6716–6720.
- Lin, J.S., Sakai, K., Vanni-Mercier, G., Jouvet, M., 1989. A critical role of the posterior hypothalamus in the mechanisms of wakefulness determined by microinjection of muscimol in freely moving cats. *Brain Res.* 479, 225–240.
- Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P.J., Nishino, S., Mignot, E., 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98, 365–376.
- Lu, X.Y., Bagnol, D., Burke, S., Akil, H., Watson, S.J., 2000. Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. *Horm. Behav.* 37, 335–344.
- Marcus, J.N., Aschkenasi, C.J., Lee, C.E., Chemelli, R.M., Saper, C.B., Yanagisawa, M., Elmquist, J.K., 2001. Differential expression of orexin receptors 1 and 2 in the rat brain. *J. Comp. Neurol.* 435, 6–25.
- Mathew, S.J., Price, R.B., Charney, D.S., 2008. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. *Am. J. Med. Genet. C Semin. Med. Genet.* 148C, 89–98.
- McCormick, D.A., 1993. Actions of acetylcholine in the cerebral cortex and thalamus and implications for function. *Prog. Brain Res.* 98, 303–308.
- McGaughy, J., Sarter, M., 1998. Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: effects of physostigmine and FG 7142. *Behav. Neurosci.* 112, 1519–1525.
- McGaughy, J., Kaiser, T., Sarter, M., 1996. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. *Behav. Neurosci.* 110, 247–265.
- McGaughy, J., Decker, M.W., Sarter, M., 1999. Enhancement of attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. *Psychopharmacology (Berl)* 144, 175–182.
- McGaughy, J., Everitt, B.J., Robbins, T.W., Sarter, M., 2000. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. *Behav. Brain Res.* 115, 251–263.
- McGaughy, J., Dalley, J.W., Morrison, C.H., Everitt, B.J., Robbins, T.W., 2002. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasal infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. *J. Neurosci.* 22, 1905–1913.
- Mesulam, M., 2004. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? *Learn. Mem.* 11, 43–49.
- Mesulam, M.M., Mufson, E.J., 1984. Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. *Brain* 107 (Pt 1), 253–274.
- Mesulam, M.M., Mufson, E.J., Levey, A.I., Wainer, B.H., 1983a. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. *J. Comp. Neurol.* 214, 170–197.
- Mesulam, M.M., Mufson, E.J., Wainer, B.H., Levey, A.I., 1983b. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1–Ch6). *Neuroscience* 10, 1185–1201.
- Mesulam, M.M., Mufson, E.J., Rogers, J., 1987. Age-related shrinkage of cortically projecting cholinergic neurons: a selective effect. *Ann. Neurol.* 22, 31–36.
- Metherate, R., Ashe, J.H., 1993. Nucleus basalis stimulation facilitates thalamocortical synaptic transmission in the rat auditory cortex. *Synapse* 14, 132–143.
- Mieda, M., Williams, S.C., Sinton, C.M., Richardson, J.A., Sakurai, T., Yanagisawa, M., 2004. Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. *J. Neurosci.* 24, 10493–10501.
- Mileykovskiy, B.Y., Kiyashchenko, L.I., Siegel, J.M., 2005. Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron* 46, 787–798.
- Moore, H., Stuckman, S., Sarter, M., Bruno, J.P., 1995. Stimulation of cortical acetylcholine efflux by FG 7142 measured with repeated microdialysis sampling. *Synapse* 21, 324–331.
- Mora, F., Rolls, E.T., Burton, M.J., 1976. Modulation during learning

- of the responses of neurons in the lateral hypothalamus to the sight of food. *Exp. Neurol.* 53, 508–519.
- Mufson, E.J., Ma, S.Y., Dills, J., Cochran, E.J., Leurgans, S., Wu, J., Bennett, D.A., Jaffar, S., Gilmore, M.L., Levey, A.I., Kordower, J.H., 2002. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. *J. Comp. Neurol.* 443, 136–153.
- Muir, J.L., Dunnett, S.B., Robbins, T.W., Everitt, B.J., 1992. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. *Exp. Brain Res.* 89, 611–622.
- Naqvi, N.H., Rudrauf, D., Damasio, H., Bechara, A., 2007. Damage to the insula disrupts addiction to cigarette smoking. *Science* 315, 531–534.
- Naumann, A., Bellebaum, C., Daum, I., 2006. Cognitive deficits in narcolepsy. *J. Sleep Res.* 15, 329–338.
- Nelson, C.L., Sarter, M., Bruno, J.P., 2000. Repeated pretreatment with amphetamine sensitizes increases in cortical acetylcholine release. *Psychopharmacology (Berl)* 151, 406–415.
- Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., Mignot, E., 2000. Hypocretin (orexin) deficiency in human narcolepsy. *Lancet* 355, 39–40.
- Oken, B.S., Kishiyama, S.S., Kaye, J.A., Howieson, D.B., 1994. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging. *Neurology* 44, 657–662.
- Parasuraman, R., Warm, J.S., Dember, W.N., 1987. Vigilance: taxonomy and utility. In: Mark, L.S., Warm, J.S., Huston, R.L. (Eds.), *Ergonomics and Human Factors*. Springer Verlag, New York, pp. 11–39.
- Passetti, F., Dalley, J.W., O'Connell, M.T., Everitt, B.J., Robbins, T.W., 2000. Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attentional task. *Eur. J. Neurosci.* 12, 3051–3058.
- Pasumarthi, R., Fadel, J., 2006. Anatomical and neurochemical mediators of nicotine-induced activation of orexin neurons. *Soc. Neurosci. Abst.* 36, 369.22.
- Pasumarthi, R.K., Fadel, J., 2008. Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine. *Brain Res. Bull.* 77, 367–373.
- Pasumarthi, R.K., Reznikov, L.R., Fadel, J., 2006. Activation of orexin neurons by acute nicotine. *Eur. J. Pharmacol.* 535, 172–176.
- Peyron, C., Tighe, D.K., van den Pol, A.N., de Lecea, L., Heller, H.C., Sutcliffe, J.G., Kilduff, T.S., 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J. Neurosci.* 18, 9996–10015.
- Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., Nevsimalova, S., Aldrich, M., Reynolds, D., Albin, R., Li, R., Hungs, M., Pedrazzoli, M., Padigaru, M., Kucherlapati, M., Fan, J., Maki, R., Lammers, G.J., Bouras, C., Kucherlapati, R., Nishino, S., Mignot, E., 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat. Med.* 6, 991–997.
- Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A., Heiskanen, S., Stenberg, D., 2004. The effect of age on prepro-orexin gene expression and contents of orexin A and B in the rat brain. *Neurobiol. Aging* 25, 231–238.
- Rieger, M., Mayer, G., Gauggel, S., 2003. Attention deficits in patients with narcolepsy. *Sleep* 26, 36–43.
- Robbins, T.W., 1997. Arousal systems and attentional processes. *Biol. Psychol.* 45, 57–71.
- Robbins, T.W., McAlonan, G., Muir, J.L., Everitt, B.J., 1997. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. *Behav. Brain Res.* 83, 15–23.
- Robinson, T.E., Whishaw, I.Q., 1974. Effects of posterior hypothalamic lesions on voluntary behavior and hippocampal electroencephalograms in the rat. *J. Comp. Physiol. Psychol.* 86, 768–786.
- Rolls, E.T., Roper-Hall, A., Sanghera, M.K., 1977. Activity of neurones in the substantia innominata and lateral hypothalamus during the initiation of feeding in the monkey [proceedings]. *J. Physiol.* 272, 24P.
- Rolls, E.T., Sanghera, M.K., Roper-Hall, A., 1979. The latency of activation of neurones in the lateral hypothalamus and substantia innominata during feeding in the monkey. *Brain Res.* 164, 121–135.
- Rosin, D.L., Weston, M.C., Sevigny, C.P., Stornetta, R.L., Guyenet, P.G., 2003. Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. *J. Comp. Neurol.* 465, 593–603.
- Rossor, M.N., Svendsen, C., Hunt, S.P., Mountjoy, C.Q., Roth, M., Iversen, L.L., 1982. The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes. *Neurosci. Lett.* 28, 217–222.
- Sakurai, T., 2005. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. *Sleep Med. Rev.* 9, 231–241.
- Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., Buckingham, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terrett, J.A., Elshourbagy, N.A., Bergsma, D.J., Yanagisawa, M., 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92, 573–585.
- Sakurai, T., Nagata, R., Yamanaka, A., Kawamura, H., Tsujino, N., Muraki, Y., Kageyama, H., Kunita, S., Takahashi, S., Goto, K., Koyama, Y., Shioda, S., Yanagisawa, M., 2005. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. *Neuron* 46, 297–308.
- Sarter, M., Bruno, J.P., 1997. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. *Brain Res. Brain Res. Rev.* 23, 28–46.
- Sarter, M., Bruno, J.P., 2002. The neglected constituent of the basal forebrain corticopetal projection system: GABAergic projections. *Eur. J. Neurosci.* 15, 1867–1873.
- Sarter, M., Turchi, J., 2002. Age- and dementia-associated impairments in divided attention: psychological constructs, animal models, and underlying neuronal mechanisms. *Dement. Geriatr. Cogn. Disord.* 13, 46–58.
- Sarter, M., Givens, B., Bruno, J.P., 2001. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. *Brain Res. Brain Res. Rev.* 35, 146–160.
- Sarter, M., Bruno, J.P., Givens, B., 2003. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? *Neurobiol. Learn. Mem.* 80, 245–256.
- Sarter, M., Hasselmo, M.E., Bruno, J.P., Givens, B., 2005a. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. *Brain Res. Brain Res. Rev.* 48, 98–111.
- Sarter, M., Nelson, C.L., Bruno, J.P., 2005b. Cortical cholinergic transmission and cortical information processing in schizophrenia. *Schizophr. Bull.* 31, 117–138.
- Scammell, T.E., Estabrooke, I.V., McCarthy, M.T., Chemelli, R.M., Yanagisawa, M., Miller, M.S., Saper, C.B., 2000. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. *J. Neurosci.* 20, 8620–8628.
- Scinto, L.F., Daffner, K.R., Castro, L., Weintraub, S., Vavrik, M., Mesulam, M.M., 1994. Impairment of spatially directed attention in patients with probable Alzheimer's disease as measured by eye movements. *Arch. Neurol.* 51, 682–688.
- Siegel, J.M., Nienhuis, R., Gulyani, S., Ouyang, S., Wu, M.F., Mignot, E., Switzer, R.C., McMurry, G., Cornford, M., 1999. Neuronal degeneration in canine narcolepsy. *J. Neurosci.* 19, 248–257.

- Sutcliffe, J.G., de Lecea, L., 2002. The hypocretins: setting the arousal threshold. *Nat. Rev. Neurosci.* 3, 339–349.
- Swett, C.P., Hobson, J.A., 1968. The effects of posterior hypothalamic lesions on behavioral and electrographic manifestations of sleep and waking in cats. *Arch. Ital. Biol.* 106, 283–293.
- Szymusiak, R., 1995. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. *Sleep* 18, 478–500.
- Telegdy, G., Adamik, A., 2002. The action of orexin A on passive avoidance learning. Involvement of transmitters. *Regul. Pept.* 104, 105–110.
- Terao, A., Apte-Deshpande, A., Morairty, S., Freund, Y.R., Kilduff, T.S., 2002. Age-related decline in hypocretin (orexin) receptor 2 messenger RNA levels in the mouse brain. *Neurosci. Lett.* 332, 190–194.
- Thakkar, M.M., Ramesh, V., Strecker, R.E., McCarley, R.W., 2001. Microdialysis perfusion of orexin-A in the basal forebrain increases wakefulness in freely behaving rats. *Arch. Ital. Biol.* 139, 313–328.
- Thannickal, T.C., Moore, R.Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., Siegel, J.M., 2000. Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 27, 469–474.
- Torrealla, F., Yanagisawa, M., Saper, C.B., 2003. Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. *Neuroscience* 119, 1033–1044.
- Turchi, J., Sarter, M., 1997. Cortical acetylcholine and processing capacity: effects of cortical cholinergic deafferentation on crossmodal divided attention in rats. *Brain Res. Cogn. Brain Res.* 6, 147–158.
- Vazquez, J., Baghdoyan, H.A., 2001. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 280, R598–R601.
- Vittoz, N.M., Berridge, C.W., 2001. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. *Neuropsychopharmacology* 31, 384–395.
- Wang, Q.P., Guan, J.L., Matsuoka, T., Hirayana, Y., Shioda, S., 2003. Electron microscopic examination of the orexin immunoreactivity in the dorsal raphe nucleus. *Peptides* 24, 925–930.
- Wang, B., You, Z.B., Wise, R.A., 2009. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. *Biol. Psychiatry* 65, 857–862.
- Whitehouse, P.J., 2004. Paying attention to acetylcholine: the key to wisdom and quality of life? *Prog. Brain Res.* 145, 311–317.
- Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., Delon, M.R., 1982. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science* 215, 1237–1239.
- Williams, M.J., Adinoff, B., 2008. The role of acetylcholine in cocaine addiction. *Neuropsychopharmacology* 33, 1779–1797.
- Wu, M., Zaborszky, L., Hajszan, T., van den Pol, A.N., Alreja, M., 2004. Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. *J. Neurosci.* 24, 3527–3536.
- Wurtman, J.J., 1988. The anorexia of aging: a problem not restricted to calorie intake. *Neurobiol. Aging* 9, 22–23.
- Yamanaka, A., Muraki, Y., Tsujino, N., Goto, K., Sakurai, T., 2003. Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem. Biophys. Res. Commun.* 303, 120–129.
- Yoshida, K., McCormack, S., Espana, R.A., Crocker, A., Scammell, T.E., 2006. Afferents to the orexin neurons of the rat brain. *J. Comp. Neurol.* 494, 845–861.
- Zaborszky, L., Cullinan, W.E., 1989. Hypothalamic axons terminate on forebrain cholinergic neurons: an ultrastructural double-labeling study using PHA-L tracing and ChAT immunocytochemistry. *Brain Res.* 479, 177–184.
- Zaborszky, L., Gaykema, R.P., Swanson, D.J., Cullinan, W.E., 1997. Cortical input to the basal forebrain. *Neuroscience* 79, 1051–1078.
- Zeitler, J.M., Nishino, S., Mignot, E., 2006. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. *Trends Pharmacol. Sci.* 27, 368–374.
- Zhang, J.H., Sampogna, S., Morales, F.R., Chase, M.H., 2002. Age-related changes in hypocretin (orexin) immunoreactivity in the cat brainstem. *Brain Res.* 930, 206–211.